Iodine-131 Rituximab Non-Hodgkin's lymphoma a b s t r a c t Radioimmunotherapy is an established treatment modality in Non-Hodgkin's lymphoma. The only two commercially available radioimmunotherapies -90 Y-ibritumomab tiuxetan is expensive and 131 I-tositumomab has been discontinued from commercial production. In resource limited environment, selflabelling 131 I-rituximab might be the only viable practical option. We reported our pioneer experience in
Malaysia on self-labelling 131 I-rituximab, substituting autologous haematopoietic stem cell transplantation (HSCT) and a patient, the first reported case, received high dose 131 I-rituximab (6000 MBq/163 mCi) combined with BEAM conditioning for autologous HSCT. & 2016 Elsevier Ltd. All rights reserved.
Introduction
Radioimmunotherapy (RIT) is an established treatment modality in Non-Hodgkin's lymphoma (NHL). To date, the commer- Y-ibritumomab tiuxetan is as consolidation after achieving complete response (CR) or partial response (PR) following first line treatment (Morschhauser et al., 2008 (Morschhauser et al., , 2013 Rose et al., 2012; Provencio et al., 2014) in previously untreated follicular NHL and as the sole treatment in relapse/refractory low-grade or follicular B-cell NHL (Zinzani et al., 2010a; Vanazzi et al., 2014) . It has been used in low grade B-cell NHL as 
